Effects of long-term administration of methotrexate on bone mineral density in rheumatoid arthritis

Laura D Carbone, G. Kaeley, K. M. McKown, M. Cremer, G. Palmieri, S. Kaplan

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Because previous studies of high-dose methotrexate usage have demonstrated an effect on bone formation and resorption, this study was done to determine whether long-term, low-dose use of methotrexate for the treatment of rheumatoid arthritis causes bone loss. Bone mineral density (BMD) of the lumbar spine and hip was measured in 10 Caucasian postmenopausal women who had never received methotrexate and 10 Caucasian postmenopausal women who had received the drug for 3 or more years. There were no significant differences in BMD at the lumbar spine (L2-L4) between patients who had used long-term methotrexate compared with patients never treated with methotrexate (1.08 ± 0.08 g/cm2 versus 0.98 ± 0.14 g/cm2, respectively; P = 0.08). Similarly, there were no significant differences in BMD at the femoral neck between methotrexate users and nonusers (0.81 ± 0.08 g/cm2 versus 0.76 ± 0.15 g/cm2, respectively; P = 0.42). These results suggest that long-term low-dose methotrexate treatment for rheumatoid arthritis is not associated with accelerated bone loss.

Original languageEnglish (US)
Pages (from-to)100-101
Number of pages2
JournalCalcified Tissue International
Volume64
Issue number2
DOIs
StatePublished - Feb 8 1999
Externally publishedYes

Fingerprint

Methotrexate
Bone Density
Rheumatoid Arthritis
Spine
Bone and Bones
Femur Neck
Bone Resorption
Osteogenesis
Hip
Therapeutics
Pharmaceutical Preparations

Keywords

  • Bone loss
  • Methotrexate
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine
  • Endocrinology

Cite this

Effects of long-term administration of methotrexate on bone mineral density in rheumatoid arthritis. / Carbone, Laura D; Kaeley, G.; McKown, K. M.; Cremer, M.; Palmieri, G.; Kaplan, S.

In: Calcified Tissue International, Vol. 64, No. 2, 08.02.1999, p. 100-101.

Research output: Contribution to journalArticle

Carbone, Laura D ; Kaeley, G. ; McKown, K. M. ; Cremer, M. ; Palmieri, G. ; Kaplan, S. / Effects of long-term administration of methotrexate on bone mineral density in rheumatoid arthritis. In: Calcified Tissue International. 1999 ; Vol. 64, No. 2. pp. 100-101.
@article{334a2f3671d845039724b1678bcd8a86,
title = "Effects of long-term administration of methotrexate on bone mineral density in rheumatoid arthritis",
abstract = "Because previous studies of high-dose methotrexate usage have demonstrated an effect on bone formation and resorption, this study was done to determine whether long-term, low-dose use of methotrexate for the treatment of rheumatoid arthritis causes bone loss. Bone mineral density (BMD) of the lumbar spine and hip was measured in 10 Caucasian postmenopausal women who had never received methotrexate and 10 Caucasian postmenopausal women who had received the drug for 3 or more years. There were no significant differences in BMD at the lumbar spine (L2-L4) between patients who had used long-term methotrexate compared with patients never treated with methotrexate (1.08 ± 0.08 g/cm2 versus 0.98 ± 0.14 g/cm2, respectively; P = 0.08). Similarly, there were no significant differences in BMD at the femoral neck between methotrexate users and nonusers (0.81 ± 0.08 g/cm2 versus 0.76 ± 0.15 g/cm2, respectively; P = 0.42). These results suggest that long-term low-dose methotrexate treatment for rheumatoid arthritis is not associated with accelerated bone loss.",
keywords = "Bone loss, Methotrexate, Rheumatoid arthritis",
author = "Carbone, {Laura D} and G. Kaeley and McKown, {K. M.} and M. Cremer and G. Palmieri and S. Kaplan",
year = "1999",
month = "2",
day = "8",
doi = "10.1007/s002239900585",
language = "English (US)",
volume = "64",
pages = "100--101",
journal = "Calcified Tissue International",
issn = "0171-967X",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Effects of long-term administration of methotrexate on bone mineral density in rheumatoid arthritis

AU - Carbone, Laura D

AU - Kaeley, G.

AU - McKown, K. M.

AU - Cremer, M.

AU - Palmieri, G.

AU - Kaplan, S.

PY - 1999/2/8

Y1 - 1999/2/8

N2 - Because previous studies of high-dose methotrexate usage have demonstrated an effect on bone formation and resorption, this study was done to determine whether long-term, low-dose use of methotrexate for the treatment of rheumatoid arthritis causes bone loss. Bone mineral density (BMD) of the lumbar spine and hip was measured in 10 Caucasian postmenopausal women who had never received methotrexate and 10 Caucasian postmenopausal women who had received the drug for 3 or more years. There were no significant differences in BMD at the lumbar spine (L2-L4) between patients who had used long-term methotrexate compared with patients never treated with methotrexate (1.08 ± 0.08 g/cm2 versus 0.98 ± 0.14 g/cm2, respectively; P = 0.08). Similarly, there were no significant differences in BMD at the femoral neck between methotrexate users and nonusers (0.81 ± 0.08 g/cm2 versus 0.76 ± 0.15 g/cm2, respectively; P = 0.42). These results suggest that long-term low-dose methotrexate treatment for rheumatoid arthritis is not associated with accelerated bone loss.

AB - Because previous studies of high-dose methotrexate usage have demonstrated an effect on bone formation and resorption, this study was done to determine whether long-term, low-dose use of methotrexate for the treatment of rheumatoid arthritis causes bone loss. Bone mineral density (BMD) of the lumbar spine and hip was measured in 10 Caucasian postmenopausal women who had never received methotrexate and 10 Caucasian postmenopausal women who had received the drug for 3 or more years. There were no significant differences in BMD at the lumbar spine (L2-L4) between patients who had used long-term methotrexate compared with patients never treated with methotrexate (1.08 ± 0.08 g/cm2 versus 0.98 ± 0.14 g/cm2, respectively; P = 0.08). Similarly, there were no significant differences in BMD at the femoral neck between methotrexate users and nonusers (0.81 ± 0.08 g/cm2 versus 0.76 ± 0.15 g/cm2, respectively; P = 0.42). These results suggest that long-term low-dose methotrexate treatment for rheumatoid arthritis is not associated with accelerated bone loss.

KW - Bone loss

KW - Methotrexate

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=0032910823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032910823&partnerID=8YFLogxK

U2 - 10.1007/s002239900585

DO - 10.1007/s002239900585

M3 - Article

VL - 64

SP - 100

EP - 101

JO - Calcified Tissue International

JF - Calcified Tissue International

SN - 0171-967X

IS - 2

ER -